Changing the future of Oncology.

Sutro initiated a collaboration with Merck & Co. in July, 2018, known as MSD outside the United States and Canada, to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders. The research and development activities leverage Sutro’s proprietary cell-free protein synthesis and site-specific conjugation platforms, which facilitate precision design and rapid empirical optimization of protein conjugates, to discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.

Under the agreement, Sutro will be primarily responsible for preclinical research and Merck will gain exclusive worldwide rights to therapeutic candidates derived from the collaboration.

Under the agreement, Sutro has received total payments of more than $90 million and is eligible for future milestone payments totaling up to $1.6 billion.

 Milestones are based on the development and sale of all therapeutic candidates and all possible indications identified under the collaboration; Sutro is also eligible for tiered royalties on the sale of products.

Sutro began a collaboration with Celgene Corporation in 2012 to discover and develop Antibody Drug Conjugates (ADCs) and bispecific antibodies using Sutro’s XpressCF® and XpressCF+™ platform technologies. Bristol Myers Squibb acquired Celgene in 2019 and assumed the rights and obligations of our collaboration agreement with Celgene. There are currently four programs in the collaboration, including a clinical stage ADC targeting B-Cell Maturation Antigen (BCMA-Targeting ADC), previously disclosed by Bristol Myers Squibb. Bristol Myers Squibb holds worldwide development and commercialization rights to the BCMA-targeting ADC program and Sutro manufactures cGMP clinical supply.

Sutro has US development and commercialization rights to three preclinical stage immuno-oncology programs, BCMA-CD3, PD1-LAG3, and PD1-TIM3, with Bristol-Myers Squibb holding ex-US rights.

In September, 2014, Sutro announced a $300M+ collaboration with Merck KGaA, Darmstadt, Germany (also known as EMD Serono) discover and develop novel antibody drug conjugates for several targets in the field of oncology.

M1231 was generated using Sutro’s XpressCF® and Sutro’s XpressCF+™ cell-free protein synthesis and conjugation technologies and includes a Sutro proprietary linker-warhead. The ADC is based on Merck KGaA, Darmstadt, Germany’s strand-exchange engineered domain (SEED) antibody platform. As part of the agreement, Sutro is manufacturing the antibody and linker-warhead for the early clinical supply and is eligible for further payments and tiered royalties ranging from low to mid-single digit percentages, along with certain additional one-time royalties, on worldwide sales of any commercial products that may result from the collaboration. Merck KGaA, Darmstadt, Germany will be responsible for drug product, clinical development and, upon regulatory approval, the commercialization of this product candidate.

If you are interested in exploring partnership opportunities with Sutro, contact us at busdev@sutrobio.com